KellBenx Locks Up $2.5 Million Seed Round
KellBenx, a New York-based company developing prenatal diagnostic tests, raised $2.5 million from four investors, according to a press release. The announcement came just days after KellBenx secured an agreement with Cedars-Sinai Medical Center to develop a new blood test designed to predict the risk of premature births early in pregnancy. The test may even work in women who are not yet pregnant, said Hassan Bennani, CEO of KellBenx, in a statement. KellBenx didn’t reveal the identities of its investors, saying only that they include three biotechnology venture capital firms and one angel investor.